insights_auto
Bakit bumaba ang GNLX 7.94%?
Tingnan ang Higit pang Detalyechevron_right
GNLX:NASDAQ
Genelux Corp
$2.32
arrow_downward
-7.94%(-0.20) 1D
$2.35
arrow_upward
+1.29% (+0.030)bedtimePagkalipas ng oras ng trabaho
Sarado: Okt 14, 4:00:01 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa GNLX...
Buksan
$2.48
Mataas
$2.52
Mababa
$2.32
Mkt. cap
104.97M
Avg. na dami
243.39K
Dami
4.00
Mataas nang 52-wk
$8.54
Mababa nang 52-wk
$2.29
EPS
-$0.87
Beta
0.59
Mga natitirang share
45.24M
Bilang ng mga empleyado
26
Buksan
$2.48
Mataas
$2.52
Mababa
$2.32
Mkt. cap
104.97M
Avg. na dami
243.39K
Dami
4.00
Mataas nang 52-wk
$8.54
Mababa nang 52-wk
$2.29
EPS
-$0.87
Beta
0.59
Mga natitirang share
45.24M
Bilang ng mga empleyado
26
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
investingLive
·
5 oras ang nakalipas
US stocks might have a bigger problem than just hotter inflation
investingLive
·
16 oras ang nakalipas
S&P 500 decline extends to 100 points with tech hit particularly hard
Bloomberg.com
·
3 araw ang nakalipas
S&P 500 Wavers as Earnings Bets Offset Chip Rout: Markets Wrap
MarketWatch
·
1 buwan ang nakalipas
The S&P 500 keeps climbing on days when stocks broadly struggle. Here’s what’s going on.
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Tungkol sa Genelux Corp
CEO-
Mga Empleyado26
Itinatag2001
HeadquartersWestlake Village, California, Estados Unidos
Sektor-
Websitegenelux.com